A
Agnieszka J. Szczepek
Researcher at Humboldt University of Berlin
Publications - 132
Citations - 3154
Agnieszka J. Szczepek is an academic researcher from Humboldt University of Berlin. The author has contributed to research in topics: Tinnitus & Medicine. The author has an hindex of 29, co-authored 112 publications receiving 2649 citations. Previous affiliations of Agnieszka J. Szczepek include Cross Cancer Institute & University of Zielona Góra.
Papers
More filters
Journal ArticleDOI
In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain [published erratum appears in Blood 1995 Jun 1;85(11):3365]
P L Bergsagel,A M Smith,Agnieszka J. Szczepek,Michael J. Mant,Andrew R. Belch,Linda M. Pilarski +5 more
TL;DR: It is concluded that monoclonal B cells in the blood of myeloma patient populations include drug-resistant reservoirs of clonotypic cells that may underlie relapse.
Journal ArticleDOI
A High Frequency of Circulating B Cells Share Clonotypic Ig Heavy-Chain VDJ Rearrangements With Autologous Bone Marrow Plasma Cells in Multiple Myeloma, as Measured by Single-Cell and In Situ Reverse Transcriptase-Polymerase Chain Reaction
Agnieszka J. Szczepek,Karen Seeberger,Juanita Wizniak,Michael J. Mant,Andrew Belch,Linda M. Pilarski +5 more
TL;DR: Their high frequency in the blood, and their resistence to conventional chemotherapy suggests that the number of circulating clonotypic cells should be clinically monitored, and that therapeutic targeting of these B cells may benefit myeloma patients.
Journal ArticleDOI
In Multiple Myeloma, Clonotypic B Lymphocytes Are Detectable Among CD19+ Peripheral Blood Cells Expressing CD38, CD56, and Monotypic Ig Light Chain
P L Bergsagel,A M Smith,Agnieszka J. Szczepek,Michael J. Mant,Andrew R. Belch,Linda M. Pilarski +5 more
TL;DR: Analysis of CD45 isoform expression on CD19+ cells in the blood and BM of myeloma patients indicates a heterogeneous continuously differentiating B lineage in contrast to other Bcell malignancies such as B-cell chronic lymphocytic leukemia (B-CLL), lymphoma, or hairy cell le~kemia.
Journal ArticleDOI
CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications.
Steven P. Treon,Linda M. Pilarski,Andrew R. Belch,Abigail S. Kelliher,Frederic I. Preffer,Yoshihito Shima,Constantine S. Mitsiades,Nicholas Mitsiades,Agnieszka J. Szczepek,Leonard Ellman,David C. Harmon,Michael L. Grossbard,Kenneth C. Anderson +12 more
TL;DR: It is suggested that multiple myeloma patients with CD20 + BMPCs may benefit from rituximab therapy, and the rationale for clinical trials to examine its use withCD20-directed serotherapies in MM is examined.
Journal ArticleDOI
Systematic review of outcome domains and instruments used in clinical trials of tinnitus treatments in adults
Deborah A. Hall,Deborah A. Hall,Haúla Haider,Agnieszka J. Szczepek,Pia Lau,Sarah Rabau,Julie Jones-Diette,Julie Jones-Diette,Alain Londero,Niklas K. Edvall,Christopher R. Cederroth,Marzena Mielczarek,Thomas Fuller,Angel Batuecas-Caletrio,Petra Brueggemen,Dean M Thompson,Dean M Thompson,Arnaud Norena,Rilana F. F. Cima,Rajnikant Mehta,Rajnikant Mehta,Birgit Mazurek +21 more
TL;DR: Findings indicate poor appreciation of the basic principles of good trial design, particularly the importance of specifying what aspect of therapeutic benefit is the main outcome.